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James W. Kazura2
1Global Pediatrics Program and Division of Pediatric Infectious Diseases, Department of Pediatrics, University of Minnesota Medical School,
Minneapolis, Minnesota; 2Center for Global Health and Diseases, Case Western Reserve University, Cleveland, Ohio; 3Walter Reed Army Institute
of Research, Silver Spring, Maryland; and 4Kenya Medical Research Institute, Nairobi, Kenya
Background. IgG antibodies to pre-erythrocytic antigens are involved in prevention of infection and disease in
animal models of malaria but have not been associated with protection against disease in human malaria.
Methods. Levels of IgG antibodies to circumsporozoite protein (CSP), liver-stage antigen type 1 (LSA-1), and
thrombospondin-related adhesive protein (TRAP) were measured in 86 children in a malaria-holoendemic area of
Kenya. The children were then monitored for episodes of clinical malaria for 52 weeks.
Results. Children with high levels of IgG antibodies to CSP, LSA-1, and TRAP had a decreased risk of clinical
malaria (adjusted hazard ratio, 0.29; 95% confidence interval 0.10–0.81; P  .02), a lower incidence of clinical
malaria (P  .006), protection from clinical malaria with a parasite level of 4000 parasites/L (P  .03), and a
higher hemoglobin level at enrollment (P  .009), compared with children with lower antibody levels. Protection
against malaria morbidity was associated primarily with antibodies to CSP and LSA-1.
Conclusions. Kenyan childrenwith high levels of IgG antibodies to the pre-erythrocytic antigensCSP, LSA-1, and
TRAP have a lower risk of developing clinical malaria than children without high levels of these antibodies. The
decreased risk of clinical malaria may be mediated in part by prevention of high-density parasitemia.
Antibody-mediated protection against human Plasmo-
dium falciparum infection and disease was demon-
strated in seminal studies in which infection and
malaria-related symptoms cleared from infants with
clinical P. falciparum malaria who received immuno-
globulin obtained from African adults living in malaria-
endemic areas [1]. Protection from malaria-related dis-
ease is thought to be due primarily to antibodies directed
against blood-stage P. falciparum, since parasites from
this stage, rather than those from pre-erythrocytic
stages, underlie the pathogenesis of fever and other
symptoms of malaria-associated illness. Although stud-
ies of pre-erythrocytic immunity in animals andhumans
have focused largely on T cell–mediated immunity
[2–5], a role for antibodies to pre-erythrocytic antigens
in protection from infection and disease in humans can-
not be excluded. For example, antibodies to circum-
sporozoite protein (CSP) have been reported to impair
the liver-based differentiation of sporozoites into mero-
zoites in rodent malaria models [4, 6–9].
To date, no prospective longitudinal study conducted
in a malaria-endemic population has demonstrated that
the presence of antibodies to 1 pre-erythrocytic anti-
gen is associated with protection against onset of clinical
malaria. In a previous study of Kenyan adults, we dem-
onstrated that high levels of IgG antibodies toCSP, liver-
stage antigen type 1 (LSA-1), and thrombospondin-
related adhesive protein (TRAP) were associated with
relative protection against P. falciparum reinfection fol-
lowing cure of blood-stage infection with antimalarial
drugs [10]. Greater protection was observed with pre-
existing antibodies to all 3 antigens combined than with
antibodies to a single antigen, and levels of antibodies to
Received 21 June 2007; accepted 22 August 2007; electronically published 5
February 2008.
Potential conflicts of interest: none reported.
Financial support: National Institute of Allergy and Infectious Diseases (grant
AI43906 to J.W.K. and grant AI01572 to C.C.J.).
This study is published with the permission of the Office of the Director of the
Kenya Medical Research Institute.
Reprints or correspondence: Dr. Chandy C. John, Dept. of Pediatrics, Dept. of
Pediatrics, University of Minnesota, 420 Delaware St. SE, 850 Mayo, MMC-296,
Minneapolis, MN (ccj@umn.edu).
The Journal of Infectious Diseases 2008; 197:519–26
© 2008 by the Infectious Diseases Society of America. All rights reserved.
0022-1899/2008/19704-0005$15.00
DOI: 10.1086/526787
M A J O R A R T I C L E
Antibodies and Risk of Clinical Malaria ● JID 2008:197 (15 February) ● 519
several blood-stage antigens did not increase or diminish the
time to reinfection. Because the number of episodes of clinical
malaria decreases with increasing age and cumulative exposure
to P. falciparum in endemic areas, such as western Kenya, where
malaria transmission is stable and high [11], this earlier study
did not address the question of whether such antibodies might
be associated with protection against malaria-attributable mor-
bidity. Antibodies to pre-erythrocytic antigens could potentially
decrease malaria morbidity by reducing the invasion of the liver
by P. falciparum sporozoites or by impairing parasite develop-
ment in the liver, leading to lower levels of parasitemia. Evidence
of an association between antibodies to pre-erythrocytic anti-
gens and protection from malaria morbidity would not prove
that this relationship is causal, but it would support the notion
that strong antibody responses to CSP and other pre-
erythrocytic antigens contained in vaccines might serve as cor-
relates of protective immunity in trials of vaccines containing
CSP, TRAP, and/or LSA-1 [12–14]. To investigate these issues,
we assessed whether high levels of antibodies to these antigens,
both individually and together, were associated with protection
from P. falciparum infection and symptomatic malaria in chil-
dren in western Kenya.
SUBJECTS AND METHODS
Study site and participants. Written informed consent was
obtained from parents or guardians of all participants. Ethical
approval for the study was granted by the National Ethical Re-
view Committee at Kenya Medical Research Institute (Nairobi,
Kenya) and the Institutional ReviewBoard forHuman Studies at
University Hospitals of Cleveland (Cleveland, OH) and Case
Western Reserve University (Cleveland).
The study was conducted from August 2001 through July
2002 in the region ofKanyawegi inNyanza province, Kenya [15].
A community meeting was held to describe the study, field as-
sistants provided detailed information about the study to all
households within the area, and parents and guardians inter-
ested in the study came to our collection sites to enroll their
children. Inclusion criteria included age of3 months and8
years and permanent residence in the area. Exclusion criteria
included acute or chronic illness, current symptoms of malaria,
and use of antimalarial drugs within the previous 2 weeks. Study
participants received no compensation but did receive freemed-
ical care for malaria.
Procedures. Approximately 0.5–1 mL of blood was col-
lected at the beginning of the study. Samples were centrifuged,
and plasma was removed and stored at -80°C for antibody test-
ing. Ten L of blood was obtained to measure the hemoglobin
concentration, and blood smears were prepared to determine
blood-stage infection by microscopy, as described elsewhere
[15]. National policy at the time of study was that antimalarial
treatment should not be administered to children with asymp-
tomatic parasitemia, because the prevalence of asymptomatic
parasitemia was very high and the receipt of drug treatment
might affect development of clinical immunity. Thus, antima-
larial drug treatment was not given at enrollment. However, all
enrolled children who developed clinical malaria during the 52-
week follow-up period were given antimalarial therapy (i.e., sul-
fadoxine-pyrimethamine; amodiaquine or quinine were admin-
istered to children allergic to sulfadoxine-pyrimethamine)
recommended by the Kenya Ministry of Health.
Active surveillance for clinical malaria was conducted over a
52-week period after enrollment. Parents of children were told
to contact their village-based field assistant if their child had a
fever or chills. Village-based field assistants also asked weekly
whether any participant had fever or chills. Children with fever
or chills were seen by a clinical officer and treated with antima-
larial drugs if they had P. falciparum on a blood smear. An epi-
sode of clinical malaria was defined as self-report of fever or
chills or an axillary temperature of37.5°C, plus asexual-stage
P. falciparum on a blood smear. A second end point was defined
as fever or chills plus an asexual-stage P. falciparum density of
4000 parasites/L. This density was previously found to have
the best overall sensitivity and specificity in this area of Kenya for
fever in a large epidemiologic study ofmalariamorbidity in chil-
dren aged 1–14 years [11].
Antibodies to CSP and LSA-1 were tested using the central
repeat sequence peptides of these antigens to which individuals
from malaria-endemic areas have previously been observed to
have IgG antibodies. The (NANP)5 repeat peptide was used for
CSP [16], and the LAKEKLQGQQSDLEQERLAKEKLQEQQ-
SDLEQERLAKEKLQ (LSA-Rep) was used for LSA-1 [17]. Anti-
bodies to TRAP were tested using recombinant P. falciparum
TRAP (3D7) expressed in E. coli and provided by one of us
(D.E.L.). The gene fragment encoding amino acids D48 to K394
was amplified from the 3D7 strain of parasite genomic DNA,
using PCR with gene-specific sense and antisense primers.
Overall and IgG-subclass levels of antibodies were quantified
by ELISA, as described elsewhere [10]. Antibody levels were ex-
pressed in arbitrary units (AU) and calculated by dividing the
ODs for samples from study participants by the mean OD 3
standard deviations (SDs) for samples from40NorthAmericans
never exposed to malaria. Serum specimens obtained from 9
North Americans that had ODs representative of those of the 40
NorthAmerican sampleswere tested on individual plates as con-
trols. Control specimens were considered to be positive for an-
tibodies if the antibody level was 1.0 AU. ODs for the AU
cutoff (AU  1.0) were 0.144 for IgG antibodies to CSP, 0.078
for antibodies to LSA-1, and 0.110 for antibodies to TRAP. On
each plate, samples from study participants were tested along
with antibody-positive control samples. The following mean
ODs (SDs) were recorded for the control samples: 0.89 (0.52),
for IgG antibodies to CSP; 1.39 (0.83), for LSA-1; and 0.56
(0.38), for TRAP.
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Statistical analysis. To avoid statistical problems associated
with use of multiple comparisons defined by different antibody
threshold values, a single antibody thresholdwas set before analysis
as the primary exposure variable. This threshold was defined as a
high level (i.e., 2 AU) of IgG antibodies to all pre-erythrocytic
antigens under study (i.e., CSP, LSA-1, and TRAP). This threshold
was chosen because, in a previous study of adults fromKanyawegi,
2AUofantibodies correlatedwith timetoreinfectionwithblood-
stage P. falciparum following cure of infectionmediated by quinine
and doxycycline therapy [10]. Secondary exposure variables were
high levels of antibodies to individual antigens. The primary out-
come variable was protection from clinicalmalaria, defined as pro-
tection fromanepisodeofmalariaduring the studyperiod. Second-
ary outcome variables were clinical malaria with a parasite level of
4000 parasites/L, the incidence density of clinical malaria, and
the hemoglobin level at the time of sample collection. Primary and
secondary variableswere chosen before the analysis.With this plan,
P values for the primary and secondary end points were not ad-
justed for multiple comparisons.
Correlations between continuous variables (e.g., levels of anti-
bodies to different antigens) were assessed by Spearman rank cor-
relation analysis. Associations between categorical variables (e.g.,
presence of high levels of antibodies to specific antigens and clinical
malaria) were assessed by 2 analysis. Kaplan-Meier survival analy-
sis and the log rank test were used to compare the times to develop-
ment of P. falciparum parasitemia in study participants with and
those without high levels of IgG antibodies to pre-erythrocytic an-
tigens. The risk of the first symptomatic malaria episode was as-
sessedwithCoxproportional hazards regressionmodeling.The cu-
mulative incidence of clinical malaria episodes was assessed with
negative binomial regression analysis, in which all malaria episodes
during the 52-week period were recorded. The Stata cluster option
was used to obtain robust variance estimates that adjusted for
within-person correlation of repeatmalaria episodes. Age-adjusted
difference inhemoglobin level at enrollmentwasassessedwithmul-
tiple linear regression modeling. Age, bed net use, and malaria in-
fection status at the timeof study enrollmentwere adjusted for in all
final models.
Sample size was determined by 2-sample comparison of pro-
portions, with the following assumptions: of the children en-
rolled, 33.3% would have high levels of antibodies to all 3
pre-erythrocytic antigens; and 80% of children without high
levels of antibodies would develop clinical malaria over the 52-
week period of study. A sample size of 77 children was required
to provide 90% power to detect a 50% reduction in clinical dis-
ease in children with high levels of antibodies. Statistical analysis
was done with Stata, version 9.0 (Stata).
RESULTS
Study enrollment and follow-up. Eighty-six children (45
males and 41 females) were recruited; all were 8 years old
(mean age [SD], 5.26  1.72 years). Sixty-eight children
(79.1%) had P. falciparum parasitemia at the time of enrollment,
but none were symptomatic. Only 3 children (3.5%) lived in a
household where bed nets were used. Survival and Cox regres-
sion analyses were performed using data for all 86 participants.
Data for 3 children who moved out of the study area during the
follow-up period were censored in Cox regression analysis at the
week in which they left (weeks 6, 17, and 33). Frequency com-
parisons were performed for the 83 children who were followed
for the full study period.
IgG antibody levels and subclasses. Levels of IgG antibod-
ies to pre-erythrocytic antigens were high (table 1) but lower
than those reported previously for adults from the same area
[10]. A total of 48.8% of children had high levels (i.e.,2 AU) of
antibodies to CSP; 57.0%, to LSA-1; and 57.0%, to TRAP. IgG
antibody levels or the presence of high levels of antibodies (AU
 2) to CSP, LSA-1, or TRAP did not differ in children with or
without parasitemia at enrollment (data not shown). Levels of
IgG antibody subclasses were checked in a subset of 28 children.
Most antibodies belonged to the IgG1 and IgG3 subclasses (table
2), although IgG2 to LSA-1 and TRAP was seen in lower fre-
quencies. The proportion of children with antibodies belonging
to the various IgG subclasses was similar to the proportion re-
ported previously for adults, with the exception of IgG1 anti-
body to TRAP (21.4% of children versus 85% of adults) and
IgG2 antibody to LSA-1 (32.4% of children versus 0% of adults)
[10]. Levels of antibody to CSP and to LSA-1 were strongly cor-
Table 1. Characteristics of IgG antibodies to circumsporo-
zoite protein (CSP), liver-stage antigen type 1 (LSA-1), and
thrombospondin-related adhesive protein (TRAP) in 86
Kenyan children.
Antigen Median AU (range)
2 AU, %
of children
CSP 1.94 (0.12–21.4) 48.8
LSA-1 3.16 (0.01–61.6) 57.0
TRAP 2.72 (0.29–29.8) 57.0
NOTE. AU, arbitrary unit. See Subjects and Methods for a description of
how AU was calculated.
Table 2. Frequencies of high-level antibody responses to cir-
cumsporozoite protein (CSP), liver-stage antigen type 1 (LSA-
1), and thrombospondin-related adhesive protein (TRAP) in 28
Kenyan children, by IgG subclass.
Antigen
Frequency of high-level
antibody response by
IgG subclass, % of children
IgG1 IgG IgG3 IgG4
CSP 71.4 0 60.7 0
LSA-1 57.1 32.1 85.7 0
TRAP 21.4 7.1 89.2 0
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related (Spearman’s rho, 0.44; P  .001), whereas levels of an-
tibodies to CSP and to TRAP (Spearman’s rho, 0.11; P  .30)
and levels of antibodies to LSA-1 and to TRAP (Spearman’s rho,
0.20; P  .12) were not. Of the 3 children whomoved out of the
area, 1 had high levels of antibodies to all 3 antigens, and 2 did
not.
IgG antibodies to individual antigens and protection from
clinical malaria. Considering each of the antigens individu-
ally, a high level of IgG antibody to LSA-1 was correlated with
protection from clinical malaria (P  .02) (table 3). A similar
trend was seen with CSP (P  .16) but not with TRAP. Trends
toward protection from malaria with a parasite level of 4000
parasites/L were seen with all 3 antigens, but none reached
statistical significance (P  .05 for all). Childrenwho had a high
level of antibody to LSA-1 had fewer episodes of malaria than
children who did not (P  .02), and a similar trend was seen for
antibody to CSP but not for antibody to TRAP. Finally, hemo-
globin levels were significantly higher in childrenwho had a high
level of IgG antibody to CSP than in children who did not
(P  .004).
IgG antibodies to multiple antigens and protection from
clinical malaria. Children who had high levels of antibodies
to all 3 antigens had a decreased frequency of clinical malaria,
compared with children with high levels of antibodies to3 of
the antigens (23.5% vs. 59.1%; P  .009) (table 3). The corre-
sponding Kaplan-Meier curve is presented in figure 1. Children
with high levels of IgG antibodies to CSP, LSA-1, and TRAP
combined were also completely protected from episodes of clin-
ical malaria with a parasite level of4000 parasites/L (0% vs.
22.7% episodes; P  .03), experienced fewer episodes of clinical
malaria (0.39 vs. 1.37 episodes per person-year; P  .001), and
had a higher age-adjusted hemoglobin level (9.29 g/dL vs. 8.27
g/dL; P  .008). For all outcomes, the differences were greater
for children with high levels of antibodies to all 3 antigens com-
bined than for children with a high level of antibody to a single
antigen.
The reduced risk and incidence of clinical malaria and the
higher mean hemoglobin level in children with high levels of
antibodies to CSP, LSA-1, and TRAP remained after adjust-
ment for age, parasitemia at enrollment, and bed net use (ta-
ble 4). Adjusted risk ratios for clinical malaria with a parasite
level of 4000 parasites/L could not be calculated because
no child with high levels of antibodies to CSP, LSA-1, and
TRAP developed this outcome during the study period. The
reduced risk and incidence of clinical malaria and the ele-
vated mean hemoglobin level in children with antibodies to
CSP and LSA-1 alone were similar to those in children with
antibodies to CSP, LSA-1, and TRAP (table 4). Post hoc ex-
ploratory analysis of cutoff levels of 2 AU for any antigen
demonstrated that no levels 2 AU were associated with
greater protection against malaria.
DISCUSSION
Wepreviously examined adults from the same area of Kenya and
reported that high levels of IgG antibodies to CSP, LSA-1, and
Table 3. Clinical malaria outcomes and hemoglobin (Hb) levels in Kenyan children with and those without high
levels of IgG antibodies to circumsporozoite protein (CSP), liver-stage antigen type 1 (LSA-1), and thrombospondin-
related adhesive protein (TRAP).
Antigen, IgG
level 2 AU
No. of
children
Clinical malaria
Malaria with
parasitemiac
Cumulative malaria
incidence
Age-adjusted
Hb level
Percentage
of childrena P b
Percentage
of children P b
Episodes/
person-year P b
Mean
g/dL  SD P d
CSP
Yes 39 43.6 .16 12.8 .24 1.00 .13 8.94 (0.81) .004
No 44 59.1 22.7 1.36 8.13 (0.51)
LSA
Yes 47 40.4 .02 12.7 .15 0.94 .02 8.78 (0.84) .14
No 36 66.7 25.0 1.51 8.31 (0.53)
TRAP
Yes 43 51.1 .88 11.6 .11 1.31 .27 8.59 (0.85) .77
No 40 52.8 25.0 1.04 8.50 (0.53)
CSP, LSA-1, TRAP
Yes 17 23.5 .009 0 .03 0.41 .001 9.29 (0.88) .008
No 66 59.1 22.7 1.39 8.27 (0.50)
NOTE. AU, arbitrary unit. See Subjects and Methods for a description of how AU was calculated.
a Percentage of children who had 1 episode of clinical malaria.
b By 2 test (or Fisher’s exact test when appropriate).
c Defined as a parasite level of 4000 parasites/L.
d By multiple linear regression analysis.
522 ● JID 2008:197 (15 February) ● John et al.
TRAP, primarily those of the IgG1 and IgG3 subclasses, were
associated with protection against P. falciparum infection [10].
In the present study, we demonstrated that high levels of IgG
antibodies to the pre-erythrocytic antigens CSP, LSA-1, and
TRAP were strongly associated with a reduction in the risk of
multiple related but distinct outcomes of P. falciparum infection
in Kenyan children, including the first episode of clinical ma-
laria, the presence of clinical malaria with a parasite level of
4000 parasites/L, the cumulative incidence of clinical ma-
laria, and a decreased hemoglobin level.High levels of antibodies
to all 3 antigens were more strongly associated with protection
from symptomaticmalaria thanwere high levels of antibodies to
individual antigens. The present study is the first to examine
prospectively the association between high levels of antibodies to
multiple pre-erythrocytic antigens and protection from disease
in African children naturally exposed to P. falciparum. Our find-
ings suggest that high levels of antibodies to CSP, LSA-1, and
TRAP may be useful immune correlates of protection against P.
falciparum infection and disease in children from malaria-
endemic areas of Africa. The data provide an impetus for further
studies of this relationship in othermalaria-endemic areaswhere
vaccines will be tested and administered to infants and children.
In vitro and in vivo studies of rodent malaria models demon-
strate that antibodies to CSP or TRAP impair or prevent infec-
tion [18–21], providing biological plausibility for the idea that
antibodies to these antigens may play a role in protection from
infection and disease. Human and mouse studies also strongly
supportCD4 andCD8T cell interferon- responses as impor-
tant in protection against liver-stage malaria [5, 15, 22–24]. Our
unpublished data show that cytokine and antibody responses to
LSA-1 and TRAP do not correlate with each other, suggesting
that antibody levels are not a marker for interferon- responses
Figure 1. Risk of clinical malaria in children with and children without high levels of antibodies to circumsporozoite protein (CSP), liver-stage antigen
type 1 (LSA-1), and thrombospondin-related adhesive protein (TRAP). A high level of antibody is defined as an antibody level of 2 arbitrary units (AU).
See Subjects and Methods for a description of how AU was calculated.
Table 4. Adjusted differences in malaria-related clinical outcomes for Kenyan children with and those
without high levels of IgG antibodies to circumsporozoite protein (CSP), liver-stage antigen type 1 (LSA-1),
and thrombospondin-related adhesive protein (TRAP).
Antigens
Risk of clinical
malaria
Cumulative incidence
of malaria
(multiple episodes)
Change in
Hb level, g/dL
HR (95% CI) P a IRR (95% CI) P b Mean difference (95% CI) P c
CSP, LSA-1, TRAP 0.29 (0.10–0.81) .02 0.29 (0.11–0.74) .009 1.00 (0.25 to 1.75) .009
CSP, LSA-1 0.43 (0.21–0.88) .02 0.58 (0.31–1.08) .09 1.07 (0.45 to 1.68) .001
NOTE. All values are adjusted for age, bed net use, and parasitemia at the time of enrollment. CI, confidence interval; HR,
hazard ratio; IRR, incidence rate ratio.
a By Cox regression analysis.
b By negative binomial regression analysis.
c By multiple linear regression analysis.
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but may impair directly or indirectly the progression of P. falci-
parum from the sporozoite stage to the blood stage. A potential
mechanism for the additive effect of antibodies with different
specificities is that each acts at a different step of the parasite’s life
cycle. CSP is important in adhesion of the sporozoite to the ba-
solateral membrane of the hepatocyte [25], andmonoclonal an-
tibodies to CSP inhibit parasite invasion of hepatoma cells [6].
TRAP is essential for sporozoite gliding motility [26] and hepa-
tocyte invasion [21], and anti-TRAP antibodies have been
shown to prevent sporozoite invasion of hepatocytes [20, 21].
Antibodies to LSA-1 may increase antibody-dependent cellular
inhibition of parasite growth or increase clearance of liver-stage
merozoites before their release into the bloodstream [27]. Re-
cent work indicates that IgG1 and IgG3 antibodies—the major
subclasses observed in our study (table 2)—mediate this type of
growth inhibition [28, 29].
Among the 3 pre-erythrocytic antigens we studied, the pres-
ence of antibody to LSA-1 was most strongly associated with
protection from clinical malaria and decreased episodes of clin-
ical malaria (table 4). LSA-1 is expressed exclusively by liver-
stage P. falciparum (no mouse malarial orthologue has been de-
scribed), and antibody to the LSA-1 central repeat peptide has
been shown in one [30] but not another [31] study to be associ-
ated with protection from clinical malaria. The differences in
associationmay be attributable to transmission differences or to
differences in the levels of antibody to LSA-1 achieved in these
populations. In the present study,most children had antibody to
LSA-1, and only the presence of high levels of antibodies (in
contrast to the presence of antibodies at any level) was associated
with protection from clinical malaria. Antibody to CSP has not
been proven to be correlatedwith protection against infection or
clinical malaria in individuals in malaria-endemic areas in prior
studies [32–34]. In contrast, recent studies of the CSP-based
RTS,S/AS02 vaccine given to Mozambican children aged 1–4
years showed efficacies of 29.9% and 28.9% against clinical ma-
laria, defined as the presence of fever (temperature, 37.5°C)
and parasitemia (parasite level, 2500 parasites/L), 6 and 21
months, respectively, after vaccination [35, 36]. Levels of anti-
bodies to recombinant CSP containing a segment of the repeat
region in the RTS,S vaccine were far higher in the vaccine group,
compared with those in the control group. Vaccinated children
with the highest tertile of anti-CSP antibody titers did not differ
from those with the lowest tertiles with respect to the risk of
developing clinical malaria, but the levels in children with the
lowest tertile were still many times higher than those in naturally
exposed children. It is possible that antibodies to the repeat
NANP peptide and the recombinant CSP molecule used in the
RTS,S vaccine may not be concordant under various conditions
of natural exposure to malaria. It may also be that the “cutoff
value” for protection associated with antibodies to CSP is higher
than the standard cutoff value that distinguishes between the
presence and the absence of antibodies but is lower than the very
high levels attained with the RTS,S vaccine. In the present study
of childhood malaria and in our previous report assessing P.
falciparum infection in adults [10], nonsignificant trends toward
protection were seen in children with a high level of antibody to
CSP, which supports a possible effect of anti-CSP antibody on
both P. falciparum infection and disease in children exposed to
areas where the rate of malaria transmission is high, such as
western Kenya. It is unlikely that antibody-associated protection
was due to a general “boost” in immunity from a single recent
infection, since children with and children without parasitemia
at the time of enrollment had similar antibody levels and risks of
disease. It is possible that high levels of antibodies are markers
for other as yet undefined protective mechanisms associated
with cumulative exposure to infection, but use of these factors as
correlates of protective immunity remains valid even if this is the
case.
Immune responses such as production of antibodies to pre-
erythrocytic antigens may not completely prevent blood-stage
infection but may control the parasite density and the clonality
of parasitemia by reducing the invasion of P. falciparum sporo-
zoites into the liver or by impairing progressive development of
parasites in the liver. Previous data demonstrating increased lev-
els of anti-CSP antibodies [10] and decreasing parasite densities
[37] in asymptomatic adults in amalaria-holoendemic area sup-
port this notion. Protection from higher-density parasitemia re-
ported here supports this idea—none of the 18 children with
high levels of antibodies to CSP, LSA-1, and TRAP developed a
parasite level of4000 parasites/L during their episode of clin-
ical malaria. Protection from high-density parasitemia may be a
pathway through which partial protection against pre-
erythrocytic stages of P. falciparum reduces the burden of
malaria-related clinical illness, as lower density parasitemia may
more readily be controlled by other mechanisms of anti-disease
immunity, such as antibodies directed against variant malaria
antigens expressed on the surface of infected erythrocytes. Lower
density parasitemia may also result in a decrease in hemolysis
and/or associated bone marrow suppression, resulting in higher
hemoglobin levels.
The findings presented here raise issues relevant to the evalu-
ation and use of malaria vaccines. The degree of natural expo-
sure tomalaria required to attain high levels of IgG antibodies to
CSP, TRAP, and LSA-1 is not known. In malaria-endemic areas
with transmission rates lower than those in western Kenya, chil-
dren may not attain the levels reported here. In addition, the
reason why levels of antibodies to the different pre-erythrocytic
antigens are heterogeneous andwhy only some children develop
high levels of antibodies to all 3 antigens are not known. Differ-
ences in exposure to infective sporozoites at the household level,
as well as genetic factors, may contribute.
Finally, results of our study lend support to the goal of devel-
oping a multiple-antigen subunit or attenuated whole parasite
vaccine that includes pre-erythrocytic antigens as a target. If
524 ● JID 2008:197 (15 February) ● John et al.
multiple-antigen vaccines can induce higher levels of antibodies
and T effector cells than levels induced by natural infection or a
single-antigen vaccine, theymay improve the strength of protec-
tion from malaria-related morbidity provided by these expo-
sures.
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